** Drug developer Viridian Therapeutics' shares rise 32.4% to $23.64 premarket ** Company says its drug, veligrotug, helped to significantly relieve symptoms when tested in patients with chronic thyroid eye disease (TED) during a late-stage trial
** TED causes inflammation and damage to the tissues around the eye and is estimated to affect between 90 and 300 per 100,000 people in the U.S.
** Company plans to submit a marketing application for U.S. approval in the second half of 2025
** As of last close, stock down 18% YTD
(Reporting by Christy Santhosh) ((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。